SLN.L - Silence Therapeutics plc

LSE - LSE Delayed price. Currency in GBp

Silence Therapeutics plc

72 Hammersmith Road
London W14 8TH
United Kingdom
44 20 3457 6900

Full-time employees46

Key executives

NameTitlePayExercisedYear born
Mr. Iain Gladstone Ross BSc (Hons), C.DIR, CH.DExec. Chairman92kN/A1954
Dr. Rob QuinnCFO & Sec.N/AN/AN/A
Dr. Barbara A. RuskinSr. VP, Gen. Counsel & Chief Patent OfficerN/AN/AN/A
Ms. Linnea ElringtonVP & Head of HRN/AN/AN/A
Dr. Mark CameronHead of ChemistryN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Corporate governance

Silence Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more